CALC vs. KRON, CARM, EGRX, ANEB, IMMX, ELDN, AEON, TLSA, KZR, and MURA
Should you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Kronos Bio (KRON), Carisma Therapeutics (CARM), Eagle Pharmaceuticals (EGRX), Anebulo Pharmaceuticals (ANEB), Immix Biopharma (IMMX), Eledon Pharmaceuticals (ELDN), AEON Biopharma (AEON), Tiziana Life Sciences (TLSA), Kezar Life Sciences (KZR), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical preparations" industry.
Kronos Bio (NASDAQ:KRON) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
CalciMedica has lower revenue, but higher earnings than Kronos Bio. CalciMedica is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks.
Kronos Bio received 9 more outperform votes than CalciMedica when rated by MarketBeat users. However, 100.00% of users gave CalciMedica an outperform vote while only 66.67% of users gave Kronos Bio an outperform vote.
Kronos Bio currently has a consensus target price of $4.13, indicating a potential upside of 296.63%. CalciMedica has a consensus target price of $18.67, indicating a potential upside of 242.51%. Given CalciMedica's higher possible upside, analysts clearly believe Kronos Bio is more favorable than CalciMedica.
In the previous week, CalciMedica had 15 more articles in the media than Kronos Bio. MarketBeat recorded 17 mentions for CalciMedica and 2 mentions for Kronos Bio. Kronos Bio's average media sentiment score of 0.89 beat CalciMedica's score of 0.84 indicating that CalciMedica is being referred to more favorably in the news media.
Kronos Bio has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.
CalciMedica has a net margin of 0.00% compared to CalciMedica's net margin of -1,534.11%. CalciMedica's return on equity of -68.67% beat Kronos Bio's return on equity.
64.1% of Kronos Bio shares are held by institutional investors. 23.4% of Kronos Bio shares are held by company insiders. Comparatively, 53.3% of CalciMedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Kronos Bio beats CalciMedica on 9 of the 16 factors compared between the two stocks.
Get CalciMedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CalciMedica Competitors List
Related Companies and Tools
